4 innovative drugs approved in China involving hepatitis C, stroke, diabetes, eczema 4 diseases.

On July 30, according to a notice issued by the NMPA Drug Approval, four innovative drugs were approved for listing in China, namely, the goliath hepatitis C drug Ravidavi, the first-sounding stroke chinese medicine Idara feng right-hand ol, the Merca East sugar-lowering drug Aegrien and the Pfizer eczema drug Creboro.
1, hepatitis C new drug Ravidavir Ravidawe is the second class 1 anti-hepatitis C innovative drug independently developed by Geli, by the 13th Five-Year National Science and Technology major special "major new drug creation" special project support, its clinical trial applications have also been included in the National Drug Administration priority review process.
announced in July 2018 that it had submitted a listing application for Ravidavi to NMPA of China, in a joint use of its anti-hepatitis C class 1 innovative drug Gonovir as a hepatitis C treatment (RDV/DNV treatment), in Chinese mainland's completed II Phase III clinical trial results show that after 12 weeks of treatment, the RDV/DNV treatment option had a cure rate (SVR12) of 99% in patients with non-hepatic cirrhosis type 1, and 100% achieved SVR12 in patients with NS5A drug resistance mutations at baseline.
it is worth noting that Ravidavi has been included in the World Health Organization's guidelines for the treatment of hepatitis C.
, a member of the Chinese Academy of Engineering and a professor in the Department of Medicine of Peking University, said, "I warmly congratulate Goli on making another significant progress in the field of hepatitis C treatment."
RDV/DNV treatment program clinical research data are very exciting, especially as china's first DAA full oral interferon-free treatment program, and the efficacy is not affected by baseline NS5A drug resistance mutation, which is to improve the diagnosis rate, treatment rate of the vast number of patients with hepatitis C in China, and then in China to fully control and eliminate hepatitis C is of great significance.
" 2, stroke new drug Ida la fon right-hand ol idala fon right-hand ol injection is an innovative nerve protection agent, with a 4:1 ratio combination of scientific matching Two active ingredients, Idalafon and right-hand ol, were used to remove free agents, anti-inflammatory and improve the blood-brain barrier, which significantly reduced and improved nerve damage to the brain caused by acute ischemic stroke.
CDE website, the NDA listing application for Ida'sin November 2018.
A Phase III study involving 1,200 patients with acute ischemic stroke, double-blind, positive control, head-to-head comparison, showed clear therapeutic advantages over the one-way Idalaven rightol injection, similar clinical safety, and significantly extended the existing treatment window from 24 hours to 48 hours.
3, the new diabetes drug Aegrie net tablet is a joint research and development of SGLT-2 inhibitors by Mercer and Pfizer, this time approved, Agledge net became the fourth domestic approval of SGLT-2 inhibitors after Dagle net, Engele net and Kagele net.
ertugliflozin has shown good efficacy and safety in clinical trials.
two Phase 3 clinical trial data published by
showed that ertugliflozin significantly reduced patients' levels of hemoglobin (HbA1c) compared to the placebo control group, whether in association with metformin or with Januvia.
these results, the FDA approved Ertugliflozin, a single-drug treatment for type 2 diabetes, in 2019.
4, the new eczema drug Crisaborole, is a nonsteroidal local PDE4 inhibitor of Pfizer.
Pfizer's Creboro ointment (acceptance number: JXHS2000008) has been approved for the market to treat admissible dermatitis (wet) according to a notice issued by the NMPA drug approval. In China, Creboro was included in the list of the second batch of clinically in urgent need of new drugs from abroad, with mild to moderate specific dermatitis aged 2 years and older, and the application for listing of the product was accepted by CDE on February 10 this year.
first approved in the United States in December 2016 for the treatment of mild to moderate eczema (a.g., ad., adm. specialty dermatitis), becoming the first prescription drug for specialty dermatitis to be approved for sale in 10 years, and the first nonsteroidal in-body drug to suppress skin PDE4.
dermatitis (AD) is a chronic inflammatory skin disease commonly referred to as eczema , a common term for inflammation of several skin types.
dermatitis is the most common of many types of eczema and usually begins in childhood and can last into adulthood.
of pathogenic dermatitis is a combination of genetic, immune and environmental factors.
In endexual dermatitis, the skin develops red, scaly and cortical bulging, often very itchy;
: July 30, 2020 drug approval documents to be received information release. Retrieved 2020-07-30, from.